

**Hoechst Celanese**

RECEIVED

95 FEB 22 PM 2:57

Department of  
Environmental, Health &  
Safety Affairs (DEHSA)

A

**ORIGINAL**

Hoechst Celanese Corporation  
Route 202-206  
PO Box 2500  
Somerville, NJ 08876-1258  
908 231 2000  
Telex 833 449  
Fax 908 231 4554

February 13, 1995  
RAJ-020-95

Attn: TSCA Section 8(e) Coordinator  
Document Processing Center (TS-790)  
U.S. Environmental Protection Agency  
401 M Street, S.W.  
Washington, D.C. 20460

**Contains No CBI**

Dear Sir or Madam:

In accordance with the reporting requirements of TSCA Section 8(e), Hoechst Celanese Corporation hereby submits the preliminary results of an acute oral toxicity study in rats for  $\alpha$ -aminoethylphenol, ethoxylate (CAS no. unknown). The draft of the study report is attached.

In this study, central nervous system effects were observed at two dose levels: 5000 and 2000 mg/kg. At the 5000 mg dose, convulsions or tremors were observed in 3 of the 10 animals within 3-4 hours of administration; these 3 animals all died on day-0. At the 2000 mg dose, tremors were observed in 1 animal which died on day-1.

The use of the chemical is limited to R&D activities.

This submission contains no confidential business information.

If any further information is required, do not hesitate to contact Dr. Richard A. Jourdenais, Manager, Product Stewardship at 908-231-3746.

Sincerely,

*Susan Engelman*

Susan Engelman  
Vice President, Environmental, Health &  
Safety Affairs

RAJ/mcs  
Attachment

CERTIFIED MAIL/  
RETURN RECEIPT REQUESTED

File: Log No. 185



8EHQ-95-13341  
INIT 02/22/95

RAJ  
2/14/95



88950000130

RECEIVED  
3/15/95

Hoechst Celanese

C

UBTL, INC.  
520 WAKARA WAY  
SALT LAKE CITY, UT 84108

DRAFT REPORT

ACUTE ORAL TOXICITY STUDY  
IN RATS ADMINISTERED  
TEST ARTICLE C-01952  
p-ALPHA-AMINOETHYLPHENOL ETHOXYLATE (EAEP)

UBTL STUDY 67098  
PROTOCOL AOOECDL-010

CONFIDENTIAL CBI

PREPARED FOR

HOECHST CELANESE CORPORATION  
ROUTE 202/206, P.O. BOX 2500  
SOMERVILLE, NJ 08876-1258  
(908) 231-2813

UBTL, INC.  
520 WAKARA WAY  
SALT LAKE CITY, UT 84108

REPORT APPROVAL PAGE

---

J. Robert Mattinson, B.S.  
Study Director

---

Date

---

R. Wayne Ball, Ph.D., D.A.B.T.  
Associate Director of Toxicology

---

Date

UBTL, INC.  
520 WAKARA WAY  
SALT LAKE CITY, UT 84108

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

The portions of this study conducted at UBTL were in accordance with the OECD regulations for Good Laboratory Practice with any exceptions as listed in the Data Integrity Statement found in Appendix C.

Evaluations related to the chemical composition, purity, strength and stability of the test article or the concentration, uniformity and stability of any mixtures used were the responsibility of the Sponsor. Therefore, these evaluations were not performed by the testing facility.

---

J. Robert Mattinson, B.S.  
Study Director

---

Date

ACUTE ORAL TOXICITY STUDY IN RATS  
ADMINISTERED TEST ARTICLE C-01952  
p-ALPHA-AMINOETHYLPHENOL ETHOXYLATE (EAEP)

ABSTRACT

Undiluted test article C-01952 was administered orally to five male and five female animals at 5.0 g/kg. As significant mortality was observed, an additional dose level (2.0 g/kg) was initiated using five males and five females in order to further clarify and define the mortality and significant clinical signs.

The oral toxicity test resulted in 80% mortality in the 5.0 g/kg dose group and 10% mortality in the 2.0 g/kg dose group. Two animals in the 5.0 g/kg dose group died prior to any observations being performed on Day 0. Three animals of the 5.0 g/kg dose group and one animal of the 2.0 g/kg dose group exhibited tremors and/or convulsions on Day 0 and were found dead on Day 1. Abnormal respiration (wheezing and/or labored breathing) was exhibited by 4 animals in the 5.0 g/kg dose group and one animal in the 2.0 g/kg dose group of which four died and one (5.0 g/kg) returned to normal by study Day 1. There were no target organs which were identified as being clearly related to test article administration. Based on the results of this assay, the acute oral LD50 for test article C-01952 is considered to be greater than 2.0 g/kg and less than 5.0 g/kg.

5000 - 3 } all died  
3/10 EAEP } within 24 hr  
2000 - 1/10 - tremor

## TABLE OF CONTENTS

Report Approval.....	2
Good Laboratory Practice Compliance Statement.....	3
Abstract.....	4
Table of Contents.....	5
Objective.....	6
Procedure.....	6
Study Dates.....	7
Transformations, Calculations or Operations Performed on Data.....	7
Location of Raw Data.....	7
Results.....	7-8
Conclusion.....	8
Table 1, Mortality Data Summary.....	9-10
Table 2, In-Life Observations Summary.....	11-12
Table 3, Body Weight Data Summary.....	13-14
Table 4, Gross Necropsy Summary.....	15-16
Appendix A, Test System Specifications.....	17-18
Appendix B, Test and Control Article Descriptions.....	19
Appendix C, Data Integrity Statement.....	20
Appendix D, Study Personnel.....	21
Appendix E, Quality Assurance Statement.....	22

## OBJECTIVE

The objective of this study was to evaluate the acute oral toxicity of the test article when administered as a single dose by gavage to rats.

## PROCEDURE

Protocol AOOECDL-010 (UBTL Study 67098) was followed. This study is consistent with the OECD guidelines for testing of chemicals and the EPA (TSCA) guidelines as published in the Code of Federal Regulations (40 CFR, Part 798.1175).

Five male and five female Sprague Dawley rats for each dose level (5.0 g/kg and 2.0 g/kg) were randomly selected by a computer randomization program. Animals were selected to test based on their prefasted body weights. The animals were fasted the night immediately prior to dosing.

Undiluted test article C-01952 was administered orally to five male and five female animals at a dose level of 5.0 g/kg. The mortality was 80%; therefore, an additional dose level using five male and five female rats was performed at 2.0 g/kg. Individual dosing volumes were adjusted based upon the density of the test article and the animal's fasted body weight.

Observations were made hourly for the first 4 hours immediately after dosing and twice daily (a.m. and p.m.) for the next 13 days - a total of 14 days of observation. Observations were made in accordance with UBTL SOP.

Animal body weights were recorded at the following intervals:

- within 48 hours of receipt
- the day before dosing (prefasted)\*
- the day of dosing (fasted)\*
- week 1\*
- termination/death\*

\*Data presented in Table 3

Animals dying on test or terminated at the end of the study underwent a postmortem examination. All tissues with identified lesions (from all dose groups) were collected and preserved in 10% neutral buffered formalin for possible histopathologic examination. However, the lesions were considered to be incidental and were discarded upon consultation with the sponsor.

The Test System Specifications, Test Article Description, Data Integrity Statement, Study Personnel and Quality Assurance Statement are found in Appendices A, B, C, D and E, respectively.

### STUDY DATES

Study Start Date (Date protocol is signed by the Study Director):

02-Nov-94

Experimental Start Date (First day of dosing):

09-Nov-94

Experimental Completion Date: (last day data are collected from study):

30-Nov-94

Study Completion Date (Date final report is signed by the Study Director):

Refer to the signature page

### TRANSFORMATIONS, CALCULATIONS OR OPERATIONS PERFORMED ON DATA

Mean and standard deviation values were calculated for the body weight data.

### LOCATION OF ALL RAW DATA:

The original raw data, protocol and protocol amendment and final report for this study are maintained in the UBTL archives under Study 67098.

### RESULTS:

#### Mortality:

The following mortality was observed in the dose groups:

DOSAGE	MALE	FEMALE
5.0 g/kg	60% (3/5)	100% (5/5)
2.0 g/kg	20% (1/5)	0% (0/5)

All animal deaths occurred within one day of test article administration.

The mortality data are summarized in Table 1.

#### In-Life Observations

Two animals of the 5.0 g/kg dose group died prior to any observations being performed on Day 0.

Nine animals (1 male rat in the 5.0 g/kg dose group; 3 males and 5 females in the 2.0 g/kg dose group) appeared normal throughout the study period.

Remaining animals of both dose groups exhibited one or more of the following observations during the study period: oral discharge, stained coat, abnormal stools, abnormal respiration (wheezing and/or labored breathing), tremors, convulsions and/or lethargy.

All animals which survived the 14-day study period, appeared normal by study Day 1.

In-Life observations are summarized in Table 2.



#### Body Weight

All surviving test animals had gained weight by the end of their respective study periods.

Body weight data are summarized in Table 3.

#### Necropsy:

Animals that survived the study period were euthanized by CO<sub>2</sub>. All animals at the conclusion of the study and those that died on study were subjected to a postmortem examination.

The eleven surviving animals (two in the 5.0 g/kg dose group and nine in the 2.0 g/kg dose group) did not exhibit any visible lesions at necropsy.

The animals which died on test exhibited one or more of the following observations at necropsy: oral discharge; stained coat; gastrointestinal tract fluid and/or gas filled; enlarged cervical lymph nodes and/or discoloration of the lungs, liver and/or heart.

Necropsy data are summarized in Table 4.

#### CONCLUSION:

The oral toxicity test resulted in 80% mortality in the 5.0 g/kg dose group and 10% mortality in the 2.0 g/kg dose group. Two animals in the 5.0 g/kg dose group died prior to any observations being performed on Day 0. Three animals of the 5.0 g/kg dose group and one animal of the 2.0 g/kg dose group exhibited tremors and/or convulsions on Day 0 and were found dead on Day 1. Abnormal respiration (wheezing and/or labored breathing) was exhibited by 4 animals in the 5.0 g/kg dose group and one animal in the 2.0 g/kg dose group of which four died and one (5.0 g/kg) returned to normal by study Day 1. There were no target organs which were identified as being clearly related to test article administration. Based on the results of this assay, the acute oral LD<sub>50</sub> for test article C-01952 is considered to be greater than 2.0 g/kg and less than 5.0 g/kg.

TABLE 1  
 MORTALITY DATA SUMMARY

5.0 g/kg Dose Group

DAY	0	1	2	3	4	5	6	7	8	9	10	11	12	13
ANIMALS ALIVE	5	2	2	2	2	2	2	2	2	2	2	2	2	2
ANIMALS DEAD	5	8	8	8	8	8	8	8	8	8	8	8	8	8
PERCENTAGE DEAD	50	80	80	80	80	80	80	80	80	80	80	80	80	80
MALES ALIVE	2	2	2	2	2	2	2	2	2	2	2	2	2	2
MALES DEAD	3	3	3	3	3	3	3	3	3	3	3	3	3	3
PERCENTAGE DEAD	60	60	60	60	60	60	60	60	60	60	60	60	60	60
FEMALES ALIVE	3	0	0	0	0	0	0	0	0	0	0	0	0	0
FEMALES DEAD	2	5	5	5	5	5	5	5	5	5	5	5	5	5
PERCENTAGE DEAD	40	100	100	100	100	100	100	100	100	100	100	100	100	100

TABLE 1  
 MORTALITY DATA SUMMARY

2.0 g/kg Dose Group

DAY	0	1	2	3	4	5	6	7	8	9	10	11	12	13
ANIMALS ALIVE	10	9	9	9	9	9	9	9	9	9	9	9	9	9
ANIMALS DEAD	0	1	1	1	1	1	1	1	1	1	1	1	1	1
PERCENTAGE DEAD	0	10	10	10	10	10	10	10	10	10	10	10	10	10
MALES ALIVE	5	4	4	4	4	4	4	4	4	4	4	4	4	4
MALES DEAD	0	1	1	1	1	1	1	1	1	1	1	1	1	1
PERCENTAGE DEAD	0	20	20	20	20	20	20	20	20	20	20	20	20	20
FEMALES ALIVE	5	5	5	5	5	5	5	5	5	5	5	5	5	5
FEMALES DEAD	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PERCENTAGE DEAD	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2  
 IN-LIFE OBSERVATIONS SUMMARY  
 (days following treatment)

5.0 g/kg Dose Group

OBSERVATION	1hr*	2hr*	3hr*	4hr*	1	2	3	4	5
NORMAL	6 <sup>1</sup> / <sub>8</sub> **	5/8	3/8	2 <sup>2</sup> / <sub>5</sub>	2/2	2/2	2/2	2/2	2/2
ABNORMAL STOOLS	2/8	2/8	0/8	0/5	0/2	0/2	0/2	0/2	0/2
ABNORMAL RESPIRATION <sup>3</sup>	0/8	0/8	3/8	3/5	0/2	0/2	0/2	0/2	0/2
ORAL DISCHARGE	1/8	1/8	3/8	4/5	0/2	0/2	0/2	0/2	0/2
TREMORS	0/8	0/8	2/8	1/5	0/2	0/2	0/2	0/2	0/2
CONVULSIONS	0/8	0/8	0/8	2/5	0/2	0/2	0/2	0/2	0/2
LETHARGIC	0/8	0/8	0/8	1/5	0/2	0/2	0/2	0/2	0/2

  

OBSERVATION	6	7	8	9	10	11	12	13
NORMAL	2/2	2/2	2/2	2/2	2/2	2/2	2/2	2/2
ABNORMAL STOOLS	0/2	0/2	0/2	0/2	0/2	0/2	0/2	0/2
ABNORMAL RESPIRATION <sup>3</sup>	0/2	0/2	0/2	0/2	0/2	0/2	0/2	0/2
ORAL DISCHARGE	0/2	0/2	0/2	0/2	0/2	0/2	0/2	0/2
TREMORS	0/2	0/2	0/2	0/2	0/2	0/2	0/2	0/2
CONVULSIONS	0/2	0/2	0/2	0/2	0/2	0/2	0/2	0/2
LETHARGIC	0/2	0/2	0/2	0/2	0/2	0/2	0/2	0/2

\* Day of dosing, values given in hours

\*\* Number of animals with a given observation (A.M. and/or P.M.)/number of animals alive after the last observation of the hour or day

<sup>1</sup> Two animals died prior to 1 hour observation

<sup>2</sup> Three animals were found dead following 4 hour observation but prior to the end of the day

<sup>3</sup> Respiration observations include wheezing and/or labored breathing

TABLE 2  
 IN-LIFE OBSERVATIONS SUMMARY  
 (days following treatment)

2.0 g/kg Dose Group

OBSERVATION	1hr*	2hr*	3hr*	4hr*	1	2	3	4	5
NORMAL	10/10**	9/10	9/10	8/10	9/9	9/9	9/9	9/9	9/9
ABNORMAL RESPIRATION <sup>1</sup>	0/10	0/10	1/10	1/10	1/9	0/9	0/9	0/9	0/9
ORAL DISCHARGE	0/10	1/10	1/10	1/10	1/9	0/9	0/9	0/9	0/9
TREMORS	0/10	1/10	1/10	1/10	0/9	0/9	0/9	0/9	0/9
STAINED COAT	0/10	0/10	0/10	0/10	1/9	0/9	0/9	0/9	0/9
LETHARGIC	0/10	1/10	1/10	2/10	1/9	0/9	0/9	0/9	0/9
OBSERVATION	6	7	8	9	10	11	12	13	
NORMAL	9/9	9/9	9/9	9/9	9/9	9/9	9/9	9/9	
ABNORMAL RESPIRATION <sup>1</sup>	0/9	0/9	0/9	0/9	0/9	0/9	0/9	0/9	
ORAL DISCHARGE	0/9	0/9	0/9	0/9	0/9	0/9	0/9	0/9	
TREMORS	0/9	0/9	0/9	0/9	0/9	0/9	0/9	0/9	
STAINED COAT	0/9	0/9	0/9	0/9	0/9	0/9	0/9	0/9	
LETHARGIC	0/9	0/9	0/9	0/9	0/9	0/9	0/9	0/9	

\* Day of dosing, values given in hours

\*\* Number of animals with a given observation (A.M. and/or P.M.)/number of animals alive after the last observation of the hour or day

<sup>1</sup> Labored breathing

TABLE 3  
 BODY WEIGHT DATA SUMMARY  
 (weight in grams)

5.0 g/kg Dose Group

Animal Number	Sex	Pre-Fasted Weight	Fasted Weight	Week 1 Weight	Terminal/ Dead Weight	Weight Change
235704	M	278	257	** (0)	**	**
235721	M	272	242	** (0)	**	**
235723	M	282	259	317	361	75
235724	M	283	262	** (0)	**	**
235728	M	271	246	298	332	61
235735	F	234	211	** (0)	**	**
235736	F	230	212	** (1)	**	**
235750	F	220	201	** (1)	**	**
235758	F	231	214	** (0)	**	**
235759	F	223	208	** (1)	**	**
Male Mean±SD		277 ± 6	253 ± 9	308 ± 13*	347 ± 21*	68 ± 10*
Female Mean±SD		228 ± 6	209 ± 5	**	**	**

( ) Study Day of Death - Indicated only when animal dies on study.

\* Mean and standard deviation values do not reflect animals that died before the scheduled weighing points.

\*\* Data does not apply due to animal death

Study Weight Change = (Terminal/Death Weight) - (Pre-fasted Weight)

TABLE 3  
 BODY WEIGHT DATA SUMMARY  
 (weight in grams)

2.0 g/kg Dose Group

Animal Number	Sex	Pre-Fasted Weight	Fasted Weight	Week 1 Weight	Terminal/ Dead Weight	Weight Change
235701	M	303	276	350	374	71
235705	M	335	303	378	404	69
235710	M	333	303	** (0)	**	**
235715	M	310	280	344	370	60
235719	M	299	271	336	361	62
235742	F	244	222	271	278	34
235747	F	257	235	281	280	23
235749	F	239	215	250	269	30
235756	F	234	204	259	268	34
235757	F	250	227	272	269	19
Male Mean±SD		316 ± 17	287 ± 15	352 ± 18*	377 ± 19*	66 ± 5*
Female Mean±SD		245 ± 9	221 ± 12	267 ± 12	273 ± 6	28 ± 7

( ) Study Day of Death - Indicated only when animal dies on study.

\* Mean and standard deviation values do not reflect animals that died before the scheduled weighing points

\*\* Data does not apply due to animal death

Study Weight Change = (Terminal/Death Weight) - (Pre-fasted Weight)

TABLE 4

GROSS NECROPSY SUMMARY  
 (TS = Terminal Sacrifice)

5.0 g/kg Dose Group

<u>Animal Number</u>	<u>Study Day Of Death</u>	<u>Sex</u>	<u>Gross Necropsy Observations</u>
235704	0	M	Cervical Lymph Nodes: Enlarged approximately 2-3 times normal size Lungs: Dark red in color Liver: Dark red in color Stomach: Fluid filled
235721	0	M	Heart: Dark red (almost black) Liver: Dark red all lobes Lungs: Dark red all lobes Stomach: Fluid filled
235723	TS	M	No Visible Lesions
235724	0	M	External Examination: Clear oral discharge Stomach: Yellow fluid filled Lungs: Left apical lobe dark red, multiple spots approximately 2mm in diameter; mottling Gastrointestinal Tract: Yellow fluid filled
235728	TS	M	No Visible Lesions
235735	0	F	External Examination: Clear oral discharge Lungs: Brown spots with red mottling on all lobes Stomach: Fluid and gas filled
235736	1	F	External Examination: Clear oral discharge Stomach: Fluid filled
235750	1	F	Exrternal Examination: Clear oral discharge Stomach: Fluid filled
235758	0	F	Cervical Lymph Nodes: Enlarged approximately 2 times normal size Stomach: Fluid filled
235759	1	F	External Examination: Cleaar oral discharge Stomach: Fluid filled



TABLE 4  
 GROSS NECROPSY SUMMARY  
 (TS = Terminal Sacrifice)

2.0 g/kg Dose Group

<u>Animal Number</u>	<u>Study Day Of Death</u>	<u>Sex</u>	<u>Gross Necropsy Observations</u>
235701	TS	M	No Visible Lesions
235705	TS	M	No Visible Lesions
235710	1	M	External Examination: Wet yellow material around mouth; slight yellow staining, anogenital region Stomach: Fluid filled
235715	TS	M	No Visible Lesions
235719	TS	M	No Visible Lesions
235742	TS	F	No Visible Lesions
235747	TS	F	No Visible Lesions
235749	TS	F	No Visible Lesions
235756	TS	F	No Visible Lesions
235757	TS	F	No Visible Lesions

APPENDIX A  
TEST SYSTEM SPECIFICATIONS

ANIMAL DESCRIPTION (Study Specific)

Species: Rat

Strain: Sprague Dawley

Number/Sex: 5.0 g/kg: 5 males and 5 females  
2.0 g/kg: 5 males and 5 females

Source: Healthy animals were obtained from Charles River, Portage, MI.

Age: Young Adults

Body Weight Range: 5.0 g/kg: 220-283 grams at pre-fast.  
2.0 g/kg: 234-335 grams at pre-fast.  
Animal weights fell within 20% of the group mean.

Acclimation Period: 7 days for animals in the 5.0 g/kg dose group and 14 days for animals in the 2.0 g/kg dose group.

Animal Identification: Each animal was assigned a unique number. This number was permanently indicated on each animal with an ear tag.

Method of Euthanasia: Euthanasia was accomplished using carbon dioxide

HUSBANDRY DESCRIPTION (Protocol Specific)

Room: Animals were housed separately from any other species.

Caging: Individually housed in stainless steel, wire mesh bottom cages.

Climate: Animal room air was 100% fresh with not less than 10 air changes per hour.

Temperature: 64°F - 79°F

Humidity: 30% - 70% relative humidity (per OECD)

Light: 12/12 hour, light/dark cycle

Monitoring: Animal room temperature and humidity were monitored daily with a minimum/maximum thermometer. Humidity was recorded daily.

APPENDIX A  
TEST SYSTEM SPECIFICATIONS  
(Continued)

Maintenance:	Animal rooms were cleaned at least three times per week.
Feed:	Fresh certified Agway rodent feed was provided <u>ad libitum</u> , except feed was withheld the night prior to dosing.
Water:	Fresh potable water was provided <u>ad libitum</u> .

APPENDIX B

TEST ARTICLE DESCRIPTION  
(as provided by Sponsor)

Test Article Code Number:	C-01952
Chemical Name:	p-Alpha-Aminoethylphenol Ethoxylate (EAEP)
SN Number:	SN-11357
Physical Description:	Slight yellow, viscous liquid
Density <sup>1</sup> :	1.1279 g/ml
pH <sup>2</sup> :	6
Stability:	Stable at room temperature
Solubility:	Soluble in water
Storage conditions:	Keep away from heat, sparks and flames.
Handling Precautions:	Avoid contact with skin and eyes. Wear NIOSH-approved respirator.
Characteristics:	Characterization of each lot or batch before its use in the study, documentation of synthesis, determination of solubility (when relevant) and stability both before the experimental starting date or concurrently were the responsibility of the sponsor.
Reserve Sample:	A reserve sample of each batch and/or lot of test article was collected prior to use. The reserve sample shall be maintained in archives.

<sup>1</sup> As determined by UBTL according to SOP TA-040

<sup>2</sup> As determined by UBTL using pHydrion paper (0-13)

APPENDIX C  
DATA INTEGRITY STATEMENT

Deviations

Postmortem weights on three animals which were found on study Day 1 were not collected.

The a.m. and p.m. observations for the two surviving animals dosed at 5.0 g/kg on one day of the study period were not performed 4 hours apart as per UBTL SOP.

Integrity Conclusion

The Study Director does not believe that the deviations listed above have adversely affected the quality or integrity of the data in this study.

APPENDIX D  
STUDY PERSONNEL

Study Director: 1. J. Robert Mattinson, B.S.

Other Scientists,  
Professionals or  
Supervisors:

2. R. Wayne Ball, Ph.D., D.A.B.T., Associate Director  
of Toxicology
3. Sheryl M. Dutson, M.S., Manager of Toxicology
4. Amanda Sarwacinski, B.A., Technician
5. Athena C. D. Webster, B.S., Technician
6. Ada M. Alvarado, Assistant Technician

APPENDIX E

UBTL, INC  
520 WAKARA WAY  
SALT LAKE CITY, UT 84108

QUALITY ASSURANCE STATEMENT

Study: 67098  
Protocol: AOOECDL-010

Study Title: Acute Oral Toxicity Study in Rats Administered Test Article  
C-01952, p-Alpha-Aminoethylphenol Ethoxylate (EAEP)

This study was inspected by the Quality Assurance Unit and the findings of the inspections were reported to the management and to the Study Director on the dates given below.

<u>Phase Inspected</u>	<u>Date Inspected</u>	<u>Date Reported</u>
Protocol	02 Nov 94	02 Nov 94
Dosing	09 Nov 94	09 Nov 94
Observations	09 Nov 94	09 Nov 94
Necropsy	23 Nov 94	23 Nov 94
Body Weights	14 Nov 94	14 Nov 94
Dosing	16 Nov 94	16 Nov 94
Protocol Amendment	27 Dec 94	27 Dec 94
Data/Draft Report	19 Jan 95	19 Jan 95

---

Lynn M. Kolhepp, B.S.  
Quality Assurance

---

Date



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

Susan P. Engelman  
Vice President  
Environmental Health & Safety Affairs  
Hoechst Celanese Corporation  
Route 202-206  
P.O. Box 2500  
Somerville, New Jersey 08876-1258

OFFICE OF  
PREVENTION, PESTICIDES AND  
TOXIC SUBSTANCES

APR 24 1995

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)  
Attn: TSCA Section 8(e) Coordinator  
Office of Pollution Prevention and Toxics  
U.S. Environmental Protection Agency  
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

*Terry R. O'Bryan*

Terry R. O'Bryan  
Risk Analysis Branch

Enclosure

13341A



Recycled/Recyclable  
Printed with Soy/Canola Ink on paper that  
contains at least 50% recycled fiber



### Triage of 8(e) Submissions

Date sent to triage: 12/14/95

**NON-CAP**

CAP

Submission number: 13341A

TSCA Inventory:

Y

N

**D**

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO

AQUATO

Group 2 - Ernie Falke (1 copy total)

**ATOX**

SBTOX

SEN

**w/NEUR**

Group 3 - Elizabeth Margosches (1 copy each)

STOX

CTOX

EPI

RTOX

GTOX

STOX/ONCO

CTOX/ONCO

IMMUNO

CYTO

NEUR

Other (FATE, EXPO, MET, etc.):

Notes:

**THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY**

For Contractor Use Only

entire document:

**0**

1

2

pages

**Red Dot**

pages

**1, tabs**

Notes:

Contractor reviewer :

**LPS**

Date:

**4/14/95**

CECATS/TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: Submission # 8EHQ-0295-13341 SEQ. A

TYPE INT SUPP FLWP

SUBMITTER NAME: Hoechst Celanese  
Corporation

INFORMATION REQUESTED: FLWP DATE:  
0501 NO INFO REQUESTED  
0502 INFO REQUESTED (TECH)  
0503 INFO REQUESTED (VOL ACTIONS)  
0504 INFO REQUESTED (REPORTING RATIONALE)

DISPOSITION:  
0639 REFER TO CHEMICAL SCREENING  
0678 CAP NOTICE

SUB. DATE: 02/13/95 OTS DATE: 02/22/95 CSRAD DATE: 03/15/95

CHEMICAL NAME:

Phenol, alpha-aminophenyl-, ethoxylate  
C-0152

CASE#

Unknown  
"

VOLUNTARY ACTIONS:

- 0401 NO ACTION REPORTED
- 0402 STUDIES PLANNED/IN PROGRESS
- 0403 NOTIFICATION OF WORKING CHANGES
- 0404 LABEL/MSDS CHANGES
- 0405 PROCESS/ANALYTICAL CHANGES
- 0406 APP/USE DISCONTINUED
- 0407 PRODUCTION DISCONTINUED
- 0408 CONFIDENTIAL

P F C  
01 02 04  
01 02 04  
01 02 04  
01 02 04  
01 02 04  
01 02 04  
01 02 04  
01 02 04  
01 02 04  
01 02 04

INFORMATION TYPE:

- 0241 IMMUNO (ANIMAL)
- 0242 IMMUNO (HUMAN)
- 0243 CHEM/PHYS PROP
- 0244 CLASTO (IN VITRO)
- 0245 CLASTO (ANIMAL)
- 0246 CLASTO (HUMAN)
- 0247 DNA DAM/REPAIR
- 0248 PROD/USE/PROC
- 0251 MSDS
- 0299 OTHER

P F C

- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04

INFORMATION TYPE:

- 0216 EPICLIN
- 0217 HUMAN EXPOS (PROD CONTAM)
- 0218 HUMAN EXPOS (ACCIDENTAL)
- 0219 HUMAN EXPOS (MONITORING)
- 0220 ECO/AQUA TOX
- 0221 ENV. OCCURRENCE/FATE
- 0222 EMER INCI OF ENV CONTAM
- 0223 RESPONSE REQUEST DELAY
- 0224 PROD/COMP/CHEM ID
- 0225 REPORTING RATIONALE
- 0226 CONFIDENTIAL
- 0227 ALLERG (HUMAN)
- 0228 ALLERG (ANIMAL)
- 0229 METAB/PHARMACO (ANIMAL)
- 0240 METAB/PHARMACO (HUMAN)

P F C

- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04
- 01 02 04

INFORMATION TYPE:

- 0201 ONCO (HUMAN)
- 0202 ONCO (ANIMAL)
- 0203 CELL TRANS (IN VITRO)
- 0204 MUTA (IN VITRO)
- 0205 MUTA (IN VIVO)
- 0206 REPRO/TERATO (HUMAN)
- 0207 REPRO/TERATO (ANIMAL)
- 0208 NEURO (HUMAN)
- 0209 NEURO (ANIMAL)
- 0210 ACUTE TOX. (HUMAN)
- 0211 CHR. TOX. (HUMAN)
- 0212 ACUTE TOX. (ANIMAL)
- 0213 SUB ACUTE TOX (ANIMAL)
- 0214 SUB CHRONIC TOX (ANIMAL)
- 0215 CHRONIC TOX (ANIMAL)

USE: R&D

TOXICOLOGICAL CONCERN:

LOW  
MED  
HIGH

SPECIES

RAT

ONGOING REVIEW

YES (DROP/REFER)  
NO (CONTINUE)

TRIAGE DATA NON-CBI INVENTORY

CAS SR YES NO

IN HUMAN

Non-Cap

REFR

TD9607A

13341A

L

Acute oral toxicity in the rat is of low concern. Sprague-Dawley rats (5/sex/dose) received single doses of 5,000 or 2,000 mg/kg. At 2,000 mg/kg, 1/10 animals died (1M) and at 5,000 mg/kg, 8/10 animals died (3/5 males and 5/5 females). Clinical signs included tremors and/or convulsions (1/10 at 2,000 mg/kg and 3/10 at 5,000 mg/kg), wheezing or labored respiration (1/10 at 2,000 mg/kg and 4/10 at 5,000 mg/kg), oral discharge, and lethargy. Histopathologic changes were seen at 5,000 mg/kg only in the lungs and liver (discolored), stomach (fluid-filled), and cervical lymph nodes (enlarged).